CREB: A Multifaceted Target for Alzheimer's Disease

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Alzheimer's disease (AD) involves neuronal death, amyloid plaques, tau tangles, and neuroinflammation.
• Current AD treatments are limited, driving research for novel therapeutic targets.
• The cyclic AMP/protein kinase A-cAMP response element-binding protein (cAMP/PKA/CREB) pathway is downregulated in AD.

Purpose of the Study:

• To investigate the role of the cAMP/PKA/CREB pathway in AD pathogenesis.
• To highlight CREB's influence on key pathological markers of Alzheimer's disease.
• To explore the therapeutic potential of targeting CREB signaling in neurodegenerative diseases.

Main Methods:

• Literature review and analysis of existing research on CREB signaling in AD.
• Examination of CREB's involvement in neuronal growth, plasticity, memory, and survival.
• Correlation of CREB pathway dysfunction with AD pathology, including amyloid-beta and tau.

Main Results:

• CREB is vital for neuronal survival, synaptic plasticity, and memory formation.
• Impaired CREB signaling is linked to various neurological conditions, including AD.
• The CREB pathway influences major AD pathological markers like amyloid-beta and neuroinflammation.

Conclusions:

• The cAMP/PKA/CREB pathway is a significant therapeutic target for Alzheimer's disease.
• Restoring CREB signaling may offer a novel strategy for treating cognitive deficits in AD.
• Cyclic nucleotide signaling holds potential for broader neurodegenerative disorder treatments.